Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Abstract: A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.

Abstract: A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.

Abstract: A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer.

Abstract: There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for preventing and/or treating cancer using the same, and an anti-EGFR scFv fragment.

Abstract: There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Abstract: Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.

Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.

Abstract: Provided is a method of disrupting cells comprising adding gold nanorods to a solution containing cells and irradiating the gold nanorods with a laser to disrupt the cells. A method and an apparatus for continuously disrupting cells and amplifying nucleic acids in a single microchamber are also provided, wherein the method comprises introducing a solution containing cells and gold nanorods into a microchamber, irradiating a laser onto the gold nanorods to disrupt the cells, and amplifying a nucleic acid from the disrupted cells in the microchamber. The apparatus comprises a cell disruption chamber comprising a sample inlet, and gold nanorods introduced therein; a laser attached to the cell disruption chamber, wherein the laser is for generating light at a wavelength absorbed by the gold nanorods; and a heater and a cooler for heating and cooling the cell disruption chamber. Also disclosed is a lab-on-a chip comprising the apparatus.

Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.

Abstract: An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods.

Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.

Abstract: An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided.

Abstract: The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including, but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinsitol, cardiolipin, cholesterol, and sphingomyelin.

Abstract: Provided is a method of disrupting cells comprising adding gold nanorods to a solution containing cells and irradiating the gold nanorods with a laser to disrupt the cells. A method and an apparatus for continuously disrupting cells and amplifying nucleic acids in a single microchamber are also provided, wherein the method comprises introducing a solution containing cells and gold nanorods into a microchamber, irradiating a laser onto the gold nanorods to disrupt the cells, and amplifying a nucleic acid from the disrupted cells in the microchamber.

Abstract: Provided is a method of disrupting cells comprising adding gold nanorods to a solution containing cells and irradiating the gold nanorods with a laser to disrupt the cells. A method and an apparatus for continuously disrupting cells and amplifying nucleic acids in a single microchamber are also provided, wherein the method comprises introducing a solution containing cells and gold nanorods into a microchamber, irradiating a laser onto the gold nanorods to disrupt the cells, and amplifying a nucleic acid from the disrupted cells in the microchamber.

Abstract: A cell co-culture apparatus and a method of co-culturing and isolating cells using the cell co-culture apparatus to research interactions between cells by direct contact between the cells are provided. The cell co-culture apparatus includes a first substrate including a substrate portion and a plurality of projections provided on a surface of the substrate portion, each of the projections having a top surface for culturing cells, a second substrate including a same number of first channels as a number of the projections such that the channels fit with the projections and substrate surfaces formed between the first channels, and a third substrate including a plurality of second channels corresponding with the top surfaces and a plurality of third channels corresponding with the substrate surfaces.